Grant: Discovery Grants Program - Individual
University of Guelph
$42,000.00
Carbohydrate-based anti cancer vaccines
FY 2007-08
Summary
The main goal of our research is the development through chemical synthesis of safe vaccines against cancer. Abnormal sugar polymers (called oligosaccharides) are found at the surface of tumor cells. They are called Tumor Associated Carbohydrate Antigens (TACAs) because they can be involved in immune responses in which they are recognized as antigens (foreign structures) by the immune system. Such immune reactions result in the production of antibodies that bind specifically to three-dimensional structures displayed by the antigen and that are called epitopes. In turn, the binding of antibodies to the epitopes displayed on the tumor cell is the first step that leads to cell destruction by the immune system. Carbohydrate-based anti-tumor vaccination consists of training the immune system to recognize the unusual sugars that are displayed at the surface of tumor cells to trigger cell destruction. However, some TACAs such as dimeric Lewis X and Lewis A-Lewis X are large oligosaccharides that also contain the smaller structures Lewis X and Lewis A, respectively, that are expressed on normal cells. Therefore, if used as anti-cancer vaccines, these TACAs are likely to trigger immune reactions that can potentially lead to the destruction of normal cells. We propose two original approaches to design anti-cancer vaccines based on dimeric Lewis X and Lewis A-Lewis X: 1. To synthesize and study analogues of dimLeX and LeALeX in which any one of the three sugars defining the LeX or the LeA trisaccharides is replaced by another sugar residue (i.e. GlcNAc by Glu, Gal by Glu, Fuc by Rha). These analogues could retain internal epitopes also present in dimLeX and LeALeX but they will no longer carry the LeX or the LeA antigens at their non-reducing end. 2. To prepare and study truncated structures of dimLeX and LeALeX to discover and map internal Tumor Associated Carbohydrate Epitopes (TACEs) that can be used to target the full hexasaccharide displayed at the surface of cancer cells without trigerring an immune response against the natural antigens LeX and LeA.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
238355-2006
Name nom
Auzanneau, FranceIsabelle
Department département
Chemistry
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2006
Award amount
42000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3702
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Carbohydrates
Research subject fr
Glucides
Partie
2
Nb partie
5
Application title
Carbohydrate-based anti cancer vaccines
Keyword
NA
Application summary
The main goal of our research is the development through chemical synthesis of safe vaccines against cancer. Abnormal sugar polymers (called oligosaccharides) are found at the surface of tumor cells. They are called Tumor Associated Carbohydrate Antigens (TACAs) because they can be involved in immune responses in which they are recognized as antigens (foreign structures) by the immune system. Such immune reactions result in the production of antibodies that bind specifically to three-dimensional structures displayed by the antigen and that are called epitopes. In turn, the binding of antibodies to the epitopes displayed on the tumor cell is the first step that leads to cell destruction by the immune system. Carbohydrate-based anti-tumor vaccination consists of training the immune system to recognize the unusual sugars that are displayed at the surface of tumor cells to trigger cell destruction. However, some TACAs such as dimeric Lewis X and Lewis A-Lewis X are large oligosaccharides that also contain the smaller structures Lewis X and Lewis A, respectively, that are expressed on normal cells. Therefore, if used as anti-cancer vaccines, these TACAs are likely to trigger immune reactions that can potentially lead to the destruction of normal cells. We propose two original approaches to design anti-cancer vaccines based on dimeric Lewis X and Lewis A-Lewis X: 1. To synthesize and study analogues of dimLeX and LeALeX in which any one of the three sugars defining the LeX or the LeA trisaccharides is replaced by another sugar residue (i.e. GlcNAc by Glu, Gal by Glu, Fuc by Rha). These analogues could retain internal epitopes also present in dimLeX and LeALeX but they will no longer carry the LeX or the LeA antigens at their non-reducing end. 2. To prepare and study truncated structures of dimLeX and LeALeX to discover and map internal Tumor Associated Carbohydrate Epitopes (TACEs) that can be used to target the full hexasaccharide displayed at the surface of cancer cells without trigerring an immune response against the natural antigens LeX and LeA.